TAIPEI – October 30, 2026 -- HanchorBio (TWSE: 7827) has received Taiwan Food and Drug Administration approval for the Investigational New Drug application for HCB303, its trispecific TIGIT-Fc ligand-trap fusion protein, following U.S. FDA clearance. The approval was granted to its wholly owned subsidiary, FBD Biologics Limited, and gives the asset regulatory authorization for clinical investigation in two jurisdictions.